KEGG DRUG: Pharmacogenomic Biomarkers in FDA Drug Lables

Drug	ATC	KEGG	Efficacy	Biomarker
Busulfan	L01AB01	D00248	Antineoplastics	Philadelphia chromosome (BCR-ABL fusion gene) negative
Rituximab	L01XC02	D02994	Antineoplastics	CD20 positive
Trastuzumab	L01XC03	D03257	Antineoplastics	HER2 overexpression or gene amplification positive
Cetuximab	L01XC06	D03455	Antineoplastics	EGFR expression positive KRAS exon 2 codon 12/13 mutation negative
Panitumumab	L01XC08	D05350	Antineoplastics	EGFR expression positive KRAS exon 2 codon 12/13 mutation negative
Ofatumumab	L01XC10	D09314	Antineoplastics	CD20 positive
Brentuximab vedotin	L01XC12	D09587	Antineoplastics	CD30 positive
Pertuzumab	L01XC13	D05446	Antineoplastics	HER2 overexpression positive
Trastuzumab emtansine	L01XC14	D09980	Antineoplastics	HER2 overexpression or gene amplification positive
Obinutuzumab	L01XC15	D09321	Antineoplastics	CD20 positive
Dinutuximab	L01XC16	D10559	Antineoplastics	MYCN amplification positive
Nivolumab	L01XC17	D10316	Antineoplastics	BRAF V600 mutation positive PD-L1 protein expression positive
Pembrolizumab	L01XC18	D10574	Antineoplastics	BRAF V600 mutation positive PD-L1 protein expression positive
Blinatumomab	L01XC19	D09325	Antineoplastics	Philadelphia chromosome (BCR-ABL fusion gene) negative
Imatinib	L01XE01	D01441	Antineoplastics	Philadelphia chromosome (BCR-ABL fusion gene) positive FIP1L1-PDGFRA fusion gene positive KIT mutation D816V negative PDGFR rearrangement positive
Gefitinib	L01XE02	D01977	Antineoplastics	EGFR exon 19 deletion or exon 21 L858R mutation positive
Erlotinib	L01XE03	D04023	Antineoplastics	EGFR expression positive EGFR exon 19 deletion or exon 21 L858R mutation positive
Dasatinib	L01XE06	D06414	Antineoplastics	Philadelphia chromosome positive, BCR-ABL T315I mutation positive
Lapatinib	L01XE07	D04024	Antineoplastics	HER2 overexpression positive HLA-DQA10201 or HLA-DRB10701 allele carrier
Nilotinib	L01XE08	D08953	Antineoplastics	Philadelphia chromosome (BCR-ABL fusion gene) positive UGT1A1*28 allele homozygotes
Everolimus	L01XE10 L04AA18	D02714	Antineoplastics	HER2 overexpression negative ESR1 positive
Afatinib	L01XE13	D09733	Antineoplastics	EGFR exon 19 deletion or exon 21 L858R mutation positive
Bosutinib	L01XE14	D09728	Antineoplastics	Philadelphia chromosome (BCR-ABL fusion gene) positive
Vemurafenib	L01XE15	D09996	Antineoplastics	BRAF V600E mutation positive NRAS mutation positive
Crizotinib	L01XE16	D09731	Antineoplastics	EML4-ALK gene rearrangement positive
Dabrafenib	L01XE23	D10104	Antineoplastics	BRAF V600E mutation positive G6PD deficient
Ponatinib	L01XE24	D09951	Antineoplastics	Philadelphia chromosome positive, BCR-ABL T315I mutation positive
Trametinib	L01XE25	D10176	Antineoplastics	BRAF V600E/K mutation positive
Cabozantinib	L01XE26	D10095	Antineoplastics	RET mutation positive
Ibrutinib	L01XE27	D10223	Antineoplastics	Chromosome 17p deletion positive
Ceritinib	L01XE28	D10551	Antineoplastics	ALK gene rearrangement positive
Palbociclib	L01XE33	D10372	Antineoplastics	ESR1 positive HER2 overexpression negative
Osimertinib	L01XE35	D10766	Antineoplastics	EGFR T790M mutation positive
Alectinib	L01XE36	D10450	Antineoplastics	ALK gene rearrangement positive
Cobimetinib	L01XE38	D10615	Antineoplastics	BRAF V600E/K mutation positive
Tretinoin	L01XX14	D00094	Antineoplastics	PML-RARA translocation positive
Arsenic trioxide	L01XX27	D02106	Antineoplastics	PML-RARA translocation positive
Denileukin diftitox	L01XX29	D03682	Antineoplastics	CD25 positive
Omacetaxine	L01XX40	D08956	Antineoplastics	Philadelphia chromosome (BCR-ABL fusion gene) negative
Olaparib	L01XX46	D09730	Antineoplastics	BRCA1,2 mutation positive
Belinostat	L01XX49	D08870	Antineoplastics	UGT1A1*28 allele homozygotes
Venetoclax	L01XX52	D10679	Antineoplastics	Chromosome 17p deletion positive
Tamoxifen	L02BA01	D00966	Antineoplastics	ESR1, PGR positive Factor V Leiden negative Prothrombin mutation negative
Fulvestrant	L02BA03	D01161	Antineoplastics	ESR1, PGR positive
Anastrozole	L02BG03	D00960	Antineoplastics	ESR1, PGR positive
Letrozole	L02BG04	D00964	Antineoplastics	ESR1, PGR positive
Exemestane	L02BG06	D00963	Antineoplastics	ESR1, PGR positive
Tositumomab	V10XA53	D08622	Antineoplastics	CD20 positive
Ibritumomab tiuxetan	V10XX02	D04489	Antineoplastics	CD20 positive

Drug	ATC	KEGG	Efficacy	Biomarker
Omeprazole	A02BC01	D00455 D05259	Gastrointestinal agents; Proton pump inhibitors	CYP2C19 poor metabolizer
Pantoprazole	A02BC02	D02593	Gastrointestinal agents; Proton pump inhibitors	CYP2C19 poor metabolizer
Lansoprazole	A02BC03	D00355	Gastrointestinal agents; Proton pump inhibitors	CYP2C19 intermediate or poor metabolizer
Rabeprazole	A02BC04	D00724	Gastrointestinal agents; Proton pump inhibitors	CYP2C19 poor metabolizer
Esomeprazole	A02BC05	D01984 D04056 D10120	Gastrointestinal agents; Proton pump inhibitors	CYP2C19 poor metabolizer
Dexlansoprazole	A02BC06	D08903	Gastrointestinal agents; Proton pump inhibitors	CYP2C19 poor metabolizer
Metoclopramide	A03FA01	D05008	Antiemetics	CYB5R1-4 deficient G6PD deficient
Palonosetron	A04AA05	D05343	Anti-emetic, 5-HT3 receptor antagonist	CYP2D6 poor metabolizer
Cholic acid	A05AA03	D10699	Choleretic	AKR1D1,HSD3B7,CYP27A1,AMACR,CYP7A1 deficient
PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid			Osmotic laxatives	G6PD deficient
Glibenclamide (Glyburide)	A10BB01	D00336	Antidiabetic agents	G6PD deficient
Chlorpropamide	A10BB02	D00271	Antidiabetic agents	G6PD deficient
Glipizide	A10BB07	D00335	Antidiabetic agents	G6PD deficient
Glimepiride	A10BB12	D00593	Antidiabetic agents	G6PD deficient
Carglumic acid	A16AA05	D07130	Antihyperammonemic	NAGS deficient
Velaglucerase alfa	A16AB10	D09029	Gaucher disease treatment	GBA deficient
Elosulfase	A16AB12	D10333	mucopolysaccharidosis IV treatment	GALNS deficient
Sodium phenylbutyrate	A16AX03	D05868	Antihyperammonemic	CPS,OTC,NAGS /ASS,ASL /ARG deficient
Eliglustat	A16AX10	D09893	Gaucher disease treatment	CYP2D6 ultrarapid, intermediate or poor metabolizer
Sodium phenylacetate and sodium benzoate		D10205	Antihyperammonemic	CPS,OTC,NAGS /ASS,ASL /ARG deficient
Warfarin	B01AA03	D00564	Antithrombotic agents	VKORC1 rs9923231 allele carrier CYP2C9 intermediate or poor metabolizer PROS deficient PROC deficient
Clopidogrel	B01AC04	D00769	Antithrombotic agents	CYP2C19 intermediate or poor metabolizers
Prasugrel	B01AC22	D05597	Antithrombotic agents	CYP2C19 poor metabolizer CYP2C9 variant allele carrier CYP3A5 variant allele carrier CYP2B6 variant allele carrier
Ticagrelor	B01AC24	D09017	Antithrombotic agents	CYP2C19 poor metabolizer
Eltrombopag	B02BX05	D03978	Antihemorrhagics	Factor V Leiden carrier SERPINC1 deficient
Quinidine	C01BA01	D00642 D02272	Cardiovascular agents; Antiarrhythmics	CYP2D6 poor metabolizer
Propafenone	C01BC03	D00640	Cardiovascular agents; Antiarrhythmics	CYP2D6 poor metabolizer
Hydralazine and isosorbide		D10209	Cardiovascular agents; Vasodilators	NAT1,2 slow acetylator
Propranolol	C07AA05	D00483	Cardiovascular agents; Beta blocking agents	CYP2D6 poor metabolizer
Metoprolol	C07AB02	D00601 D00635	Cardiovascular agents; Beta blocking agents	CYP2D6 poor metabolizer
Carvedilol	C07AG02	D00255 D03415	Cardiovascular agents; Beta blocking agents	CYP2D6 poor metabolizer
Pravastatin	C10AA03	D00893	Cardiovascular agents; HMG-CoA reductase inhibitors	LDLR mutation heterozygotes and homozygotes
Atorvastatin	C10AA05	D00887 D02258	Cardiovascular agents; HMG-CoA reductase inhibitors	LDLR deficient
Rosuvastatin	C10AA07	D01915	Cardiovascular agents; HMG-CoA reductase inhibitors	LDLR deficient
Mipomersen	C10AX11	D08946	Antisense ApoB-100 mRNA	LDLR mutation heterozygotes and homozygotes
Lomitapide	C10AX12	D09638	MTTP inhibitor	LDLR mutation homozygotes
Evolocumab	C10AX13	D10557	Antihyperlipidemic	LDLR mutation heterozygotes and homozygotes
Alirocumab	C10AX14	D10335	Antihyperlipidemic	LDLR mutation heterozygotes
Terbinafine	D01AE15 D01BA02	D02219	Antifungals	CYP2D6 poor metabolizer
Mafenide	D06BA03	D01166	Antiinfectives	G6PD deficient
Dapsone	D10AX05 J04BA02	D00592	Antimycobacterials	G6PD deficient
Drospirenone and ethinylestradiol	G03AA12	D09741	Hormonal agents	CYP2C19 intermediate metabolizer
Tolterodine	G04BD07	D01148	Genitourinary agents	CYP2D6 poor metabolizer
Fesoterodine	G04BD11	D08923	Genitourinary agents	CYP2D6 poor metabolizer
Parathyroid hormone	H05AA03	D05364	Antihypocalcemia	CASR positive
Sulfamethoxazole and trimethoprim	J01EE01	D00285	Antibacterials	G6PD deficient
Nalidixic acid	J01MB02	D00183	Antibacterials	G6PD deficient
Nitrofurantoin	J01XE01	D00439	Antibacterials	G6PD deficient
Voriconazole	J02AC03	D00578	Antifungals	CYP2C19 intermediate or poor metabolizer
Rifampin, isoniazid, and pyrazinamide		D10210	Antiinfective	NAT1,2 slow acetylator
Telaprevir	J05AE11	D09012	Antivirals	IL28B SNP rs12979860
Boceprevir	J05AE12	D08876	Antivirals	IL28B SNP rs12979860
Simeprevir	J05AE14	D10469	Antivirals	IL28B SNP rs12979860
Sofosbuvir	J05AX15	D10366	Antivirals	IL28B SNP rs12979860
Abacavir	J05AF06	D00891	Antivirals	HLA-B polymorphism *5701
Dolutegravir	J05AX12	D10113	Antivirals	UGT1A1 poor metabolizer
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir	J05AX66	D10582	Antivirals	IL28B SNP rs12979860
Mercaptopurine	L01BB02	D00161	Antineoplastics	TPMT polymorphism
Thioguanine	L01BB03	D06109	Antineoplastics	TPMT polymorphism
Fluorouracil	L01BC02	D00584	Antineoplastics	DPD deficient
Capecitabine	L01BC06	D01223	Antineoplastics	DPD deficient
Cisplatin	L01XA01	D00275	Antineoplastics	TPMT polymorphism
Lapatinib	L01XE07	D04024	Antineoplastics	HLA-DQA1 polymorphism 0201 HLA-DRB1 polymorphism 0701
Pazopanib	L01XE11	D05380	Antineoplastics	UGT1A1*28 allele homozygotes
Irinotecan	L01XX19	D01061	Antineoplastics	UGT1A1*28 allele carrier
Peginterferon alfa-2b	L03AB10	D02748	Immunomodulator	IL28B SNP rs12979860
Mycophenolic acid	L04AA06	D00752 D05095 D05096	Immunomodulator	HGPRT deficient
Belimumab	L04AA26	D03068	Immunomodulator	ANA positive
Azathioprine	L04AX01	D00238	Immunomodulator	TPMT polymorphism
Lenalidomide	L04AX04	D04687	Antineoplastics	Chromosome 5q deletion
Celecoxib	L01XX33 M01AH01	D00567	Antiinflammatory (NSAID)	CYP2C9 polymorphism
Flurbiprofen	M01AE09 M02AA19 R02AX01 S01BC04	D00330 D02290	Antiinflammatory (NSAID)	CYP2C9 polymorphism
Carisoprodol	M03BA02	D00768	Muscle relaxants	CYP2C19 polymorphism
Lesinurad	M04AB05	D09921	Antigout agents	CYP2C9 poor metabolizer
Pegloticase	M04AX02	D09316	Antigout agents	G6PD deficient
Sevoflurane	N01AB08	D00547	Anesthetic	RYR1 positive
Prilocaine and lidocaine	N01BB52 N01BB54	D02740	Anesthetics	CYBR1-4 deficient G6PD deficient
Tramadol	N02AX02	D01355	Analgesics	CYP2D6 poor metabolizer
Tramadol and acetaminophen	N02AX52	D09999	Analgesics	CYP2D6 poor metabolizer
Phenytoin	N03AB02	D00512 D02103	Antiepileptics	HLA-B polymorphism *1502
Carbamazepine	N03AF01	D00252	Antiepileptics	HLA-B polymorphism 1502 HLA-A polymorphism 3101
Valproic acid	N03AG01	D00399 D00304 D00710	Antiepileptics	POLG deficient CPS,OTC,NAGS /ASS,ASL /ARG deficiency
Lacosamide	N03AX18	D07299	Antiepileptics	CYP2C19 poor metabolizer
Perphenazine	N05AB03	D00503	Antipsychotics	CYP2D6 poor metabolizer
Thioridazine	N05AC02	D00798	Antipsychotics	CYP2D6 poor metabolizer
Pimozide	N05AG02	D00560	Antipsychotics	CYP2D6 poor metabolizer
Clozapine	N05AH02	D00283	Antipsychotics	CYP2D6 poor metabolizer
Risperidone	N05AX08	D00426	Antipsychotics	CYP2D6 poor metabolizer
Aripiprazole	N05AX12	D01164 D10364	Antipsychotics	CYP2D6 poor metabolizer
Brexpiprazole	N05AX13	D10309	Antipsychotics	CYP2D6 poor metabolizer
Iloperidone	N05AX14	D02666	Antipsychotics	CYP2D6 poor metabolizer
Diazepam	N05BA01	D00293	Anxiolytics	CYP2C19 polymorphism
Clobazam	N05BA09	D01253	Anxiolytics	CYP2C19 polymorphism
Desipramine	N06AA01	D00812	Antidepressants	CYP2D6 poor metabolizer
Imipramine	N06AA02	D00815	Antidepressants	CYP2D6 poor metabolizer
Clomipramine	N06AA04	D00811	Antidepressants	CYP2D6 poor metabolizer
Amitriptyline	N06AA09	D00809	Antidepressants	CYP2D6 poor metabolizer
Trimipramine	N06AA06	D02408	Antidepressants	CYP2D6 poor metabolizer
Nortriptyline	N06AA10	D00816	Antidepressants	CYP2D6 poor metabolizer
Protriptyline	N06AA11	D00484	Antidepressants	CYP2D6 poor metabolizer
Doxepin	N06AA12	D00814	Antidepressants	CYP2C19 poor metabolizer CYP2D6 polymorphism
Fluoxetine	N06AB03	D00823	Antidepressants (SSRI)	CYP2D6 poor metabolizer
Citalopram	N06AB04	D00822	Antidepressants (SSRI)	CYP2C19 poor metabolizer CYP2D6 polymorphism
Paroxetine	N06AB05	D02260 D05374 D05375	Antidepressants (SSRI)	CYP2D6 poor metabolizer
Fluvoxamine	N06AB08	D00824	Antidepressants (SSRI)	CYP2D6 poor metabolizer
Escitalopram	N06AB10	D02567	Antidepressants (SSRI)	CYP2C19 poor metabolizer CYP2D6 poor metabolizer
Nefazodone	N06AX06	D00819	Antidepressants	CYP2D6 poor metabolizer
Venlafaxine	N06AX16	D00821	Antidepressants	CYP2D6 poor metabolizer
Vortioxetine	N06AX26	D10185	Antidepressants	CYP2D6 poor metabolizer
Chlordiazepoxide and amitriptyline	N06CA01	D10207	Antidepressants	CYP2D6 poor metabolizer
Modafinil	N06BA07	D01832	Antipsychotics	CYP2D6 poor metabolizer
Atomoxetine	N06BA09	D02574	Antipsychotics	CYP2D6 poor metabolizer
Galantamine	N06DA04	D02173	Antidementia	CYP2D6 poor metabolizer
Cevimeline	N07AX03	D00661	Sjögren's syndrome dry-mouth treatment	CYP2D6 poor metabolizer
Tetrabenazine	N07XX06	D08575	Huntington's disease chorea treatment	CYP2D6 poor metabolizer
Dextromethorphan and quinidine	N07XX59	D10208	Pseudobulbar affect (PBA) treatment	CYP2D6 poor metabolizer
Chloroquine	P01BA01	D02125	Antiparasitics	G6PD deficient
Primaquine	P01BA03	D02126	Antiparasitics	G6PD deficient
Quinine sulfate	P01BC01	D02262	Antiparasitics	G6PD deficient CYP2D6 poor metabolizer
Indacaterol	R03AC18	D09319	Chronic obstructive pulmonary disease (COPD) treatment	UGT1A1 polymorphism *28
Arformoterol		D02981	Chronic obstructive pulmonary disease (COPD) treatment	UGT1A1 poor metabolizer CYP2D6 intermediate or poor metabolizer
Codeine	R05DA04	D03580	Analgesics	CYP2D6 poor metabolizer
Ivacaftor	R07AX02	D09916	Cystic fibrosis treatment	CFTR mutation (G551D)
Lumacaftor and ivacaftor	R07AX30	D10685	Cystic fibrosis treatment	CFTR mutation (F508del)
Sodium nitrite	V03AB08	D05865	Antidotes	G6PD deficient
Methylene blue	V03AB17	D02312	Antidotes	G6PD deficient
Succimer		D00572	Electrolytes	G6PD deficient
Rasburicase	V03AF07	D05704	Antihyperuricemics	G6PD deficient CYB5R1-4 deficiency

Pharmacogenomic Biomarkers in FDA Drug Labels

Companion diagnostics

Polymorphisms and germline mutations

Pathogen genes